People: Uroplasty Inc (UPI.OQ)
UPI.OQ on NASDAQ Stock Exchange Capital Market
2.28USD
1 Aug 2013
2.28USD
1 Aug 2013
Price Change (% chg)
$0.01 (+0.44%)
$0.01 (+0.44%)
Prev Close
$2.27
$2.27
Open
$2.25
$2.25
Day's High
$2.29
$2.29
Day's Low
$2.24
$2.24
Volume
600
600
Avg. Vol
19,949
19,949
52-wk High
$4.32
$4.32
52-wk Low
$1.69
$1.69
Summary
| Name | Age | Since | Current Position |
|---|---|---|---|
James Stauner |
56 | 2011 | Independent Chairman of the Board |
Robert Kill |
48 | 2013 | President, Chief Executive Officer, Acting Chief Financial Officer, Director |
Susan Holman |
58 | 2002 | Chief Operating Officer, Secretary |
Larry Heinemann |
60 | 2007 | Vice President - Sales |
Nancy Kolb |
62 | 2010 | Vice President - Global Marketing |
Marc Herregraven |
47 | 2002 | Vice President - Manufacturing |
Arie Koole |
48 | 2000 | Corporate Controller, Managing Director - Dutch Operations |
Thomas Jamison |
52 | 2000 | Independent Director |
Lee Jones |
55 | 2006 | Independent Director |
R. Patrick Maxwell |
68 | 2011 | Independent Director |
Sven Wehrwein |
2006 | Independent Director |
Biographies
| Name | Description |
|---|---|
James Stauner |
Mr. James P. Stauner is Independent Chairman of the Board of Uroplasty Inc. since November 2011. Mr. Stauner has over 30 years of experience in the healthcare industry. Since July 2005, he has been an Operating Partner with Roundtable Healthcare Partners, a private equity firm focused on the healthcare industry. Prior to joining Roundtable Healthcare Partners, Mr. Stauner held various positions between 1999 and 2005 at Cardinal Health, Inc., most recently as President of the Manufacturing Business Groups and a member of the Senior Management Operating Committee. Mr. Stauner has knowledge of the healthcare industry and of the characteristics sought by a private equity firm for investment in the healthcare industry, and experience in operating and managing a medical products business and in finance. |
Robert Kill |
Mr. Robert E. Kill is President, Chief Executive Officer, Acting Chief Financial Officer, Director of Uroplasty Inc. Mr. Kill is currently an Operating Partner with Altamont Capital Partners, a private equity firm. Prior to joining Altamont, Mr. Kill was President and Chief Executive Officer of Virtual Radiologic Corporation, a provider of technology-enabled outsourced radiology solutions. Before Virtual Radiologic, he was President of Misys Physician Systems, a developer of electronic medical record and practice management software. Mr. Kill was with Baxter Healthcare for the first ten years of his career, where he held senior leadership roles in operations, marketing and sales. |
Susan Holman |
Ms. Susan Hartjes Holman serves as Chief Operating Officer, Secretary of Uroplasty, Inc. She served as Vice President of Operations and Regulatory Affairs from November 1994 to October 2002. Previously, she served in senior management positions for pharmaceutical and device firms in the areas of operations, research, quality, and regulatory affairs. Ms. Holman is a Senior Member and a Certified Quality Auditor of the American Society for Quality, has served several years on its Executive Board and subcommittees, and is a member of the Regulatory Affairs Professionals Society and its Ethics Task Force. |
Larry Heinemann |
Mr. Larry Heinemann serves as the Vice President - Sales of Uroplasty Inc., since June 2007. He joined the company in September 1998 as Director of Sales for North and South America and since then has served in a range of senior executive positions, primarily as a Vice President in the area of sales, marketing and business development. He is a member of the Society of Urological Nursing Association (SUNA), and served on the board as an industry liaison for the Upper Midwest Chapter. He is also a board trustee of SUNA foundation. |
Nancy Kolb |
Ms. Nancy A. Kolb serves as Vice President - Global Marketing of Uroplasty Inc. From 2005 until joining Uroplasty, Ms. Kolb was Vice President of Marketing at Inlet Medical, Inc., a manufacturer of minimally interventional laparoscopic products. |
Marc Herregraven |
Mr. Marc M. Herregraven is Vice President - Manufacturing of Uroplasty Inc. since November 2002. He joined Bioplasty, Inc. in April 1992 as Plant Manager, and became Director of Manufacturing in 1994 and Director of Operations in 1999. Previously, he served with Advanced Bio-Surfaces, Inc., a Minnesota-based medical device developer, as Director of Manufacturing, and with Bio-Vascular, Inc., a Minnesota-based medical device manufacturer, in an engineering function. |
Arie Koole |
Mr. Arie J. Koole is the Corporate Controller, Managing Director - Dutch Operations Uroplasty Inc. He joined the company in 1993 and has served as Corporate Controller and Managing Director of the company's operations in The Netherlands since January 2000. From 1987 to 1993, Mr. Koole was a financial auditor with the international accounting firm Deloitte & Touche in The Netherlands. |
Thomas Jamison |
Mr. Thomas E. Jamison is Independent Director of Uroplasty, Inc., since August 2000. Mr. Jamison is a member of Fruth, Jamison & Elsass, PLLC, a business litigation firm in Minneapolis, Minnesota. From 1996 to 1999, Mr. Jamison served as an investment banker in the Corporate Finance Department of R.J. Steichen & Company. From 1991 to 1996, Mr. Jamison practiced law at Fruth & Anthony, P.A. in Minneapolis. As an investment banker for a regional broker dealer, Mr. Jamison worked with emerging companies to raise capital, analyzed their markets, their management and their business strategies and monitored their growth and business success. |
Lee Jones |
Ms. Lee A. Jones is Independent Director of Uroplasty Inc. since August 2006. Currently the President and CEO Of MikrobEX, Inc., Ms. Jones has more than 25 years of healthcare and medical device industry experience. From June 2010 until June 2011, she was a CEO-in-Residence at the University of Minnesota Venture Center. From February 2009 until June 2010, Ms. Jones was the Chief Administrative Officer of the Schulze Diabetes Institute of the University of Minnesota. From 1997 to 2005, she served as President and Chief Executive Officer of Inlet Medical, Inc. (a Cooper Surgical company since November 2005), specializing in minimally interventional laparoscopic products. Prior to joining Inlet, she had a 14-year career at Medtronic, Inc. where she held various technical and operating positions, most recently serving as Director, General Manager of Medtronic Urology/Interstim division. |
R. Patrick Maxwell |
Mr. R. Patrick Maxwell is Independent Director of Uroplasty Inc since June 2006. He has served as Chairman of the Board from June 2006 through November 2011. Mr. Maxwell has over 30 years of experience as a turnaround management specialist, an entrepreneur and executive in both the business and non-profit sectors. He has served as Chief Financial Officer of Tele Resources, Inc. since October 1996. He previously served as Chief Executive Officer of Entronix Inc., Northern Supply, Inc., and Telnet Systems, Inc. He also previously served as Chief Financial Officer of Magnum Tire Corporation, Midwest Legal Services, Inc. and Templeton and Associates, Inc. |
Sven Wehrwein |
Mr. Sven A. Wehrwein is Independent Director of Uroplasty Inc since August 2006. He has over 35 years of experience in accounting, corporate finance and investment banking. Mr. Wehrwein also serves on the board of directors of Proto Labs, Inc., a manufacturer of Internet-enabled custom molded parts, and SPS Commerce, Inc., a supply-chain management software company, both of which are reporting companies. Mr. Wehrwein also served on the board of Compellent Technologies, Inc. from 2007 until its acquisition by Dell Inc. in 2011, on the board of Vital Images, Inc. from 1997 until its acquisition by Toshiba Medical Systems Corp. in 2011, on the board of Synovis Life Technologies, Inc. from 2004 until its acquisition by Baxter International Inc. in 2012, and on the board of Image Sensing Systems, Inc. from 2006 until 2012. |
Basic Compensation
| Name | Fiscal Year Total |
|---|---|
James Stauner |
-- |
Robert Kill |
-- |
Susan Holman |
301,189 |
Larry Heinemann |
273,654 |
Nancy Kolb |
273,956 |
Marc Herregraven |
-- |
Arie Koole |
182,526 |
Thomas Jamison |
-- |
Lee Jones |
-- |
R. Patrick Maxwell |
-- |
Sven Wehrwein |
-- |
As Of 30 Mar 2012
Options Compensation
| Name | Options | Value |
|---|---|---|
James Stauner |
0 | 0 |
Robert Kill |
0 | 0 |
Susan Holman |
135,000 | 86,800 |
Larry Heinemann |
121,666 | 49,600 |
Nancy Kolb |
0 | 0 |
Marc Herregraven |
0 | 0 |
Arie Koole |
128,346 | 17,920 |
Thomas Jamison |
0 | 0 |
Lee Jones |
0 | 0 |
R. Patrick Maxwell |
0 | 0 |
Sven Wehrwein |
0 | 0 |
| Name | Shares Traded | Price |
|---|---|---|
KILL ROBERT C |
300,000 | $0.00 |
KOLB NANCY A |
25,000 | $4.11 |
KOLB NANCY A |
15,000 | $3.15 |
KOLB NANCY A |
40,000 | $4.20 |
STAUNER JAMES P |
4,000 | $0.00 |
KILL ROBERT C |
4,000 | $0.00 |
WEHRWEIN SVEN A |
4,000 | $0.00 |
JONES LEE A |
4,000 | $0.00 |
MAXWELL R PATRICK |
4,000 | $0.00 |
JAMISON THOMAS EDWARD |
4,000 | $0.00 |
KOLB NANCY A |
12,275 | $0.00 |
HOLMAN SUSAN HARTJES |
13,100 | $0.00 |
HEINEMANN LARRY R |
12,275 | $0.00 |
HERREGRAVEN MARC |
12,275 | $0.00 |
JIWANI MAHEDI A |
16,350 | $0.00 |
KAYSEN DAVID B |
51,775 | $0.00 |
HOLMAN SUSAN HARTJES |
5,100 | $3.59 |
HOLMAN SUSAN HARTJES |
5,000 | $4.72 |
JONES LEE A |
3,125 | $0.00 |
MAXWELL R PATRICK |
15,000 | $2.38 |
JAMISON THOMAS EDWARD |
15,000 | $2.38 |
KILL ROBERT C |
3,125 | $0.00 |
JAMISON THOMAS EDWARD |
3,125 | $0.00 |
STAUNER JAMES P |
3,125 | $0.00 |
MAXWELL R PATRICK |
3,125 | $0.00 |

